An Oral Treatment for Ulcerative Colitis
A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
This project is creating a new oral medicine that uses natural gut bacteria to calm inflammation for people with inflammatory bowel disease, like ulcerative colitis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project ID | NIH-11193481 on NIH RePORTER |
What this research studies
We are working to create a new kind of oral medicine that uses the body's own gut bacteria to reduce inflammation in the digestive system. This medicine aims to help people living with inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease. Current treatments for IBD can have side effects or stop working over time, so we need safer and more effective options. Our approach focuses on restoring the gut's natural balance and strengthening the intestinal barrier, which is often damaged in IBD. We believe this new therapy could offer a life-changing alternative for those struggling with these chronic conditions.
Who could benefit from this research
Good fit: Ideal candidates would be adults aged 21 and older who suffer from inflammatory bowel disease, specifically ulcerative colitis or Crohn's disease.
Not a fit: Patients without inflammatory bowel disease or those under 21 years old would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new oral medicine could provide a safer and more effective treatment option for inflammatory bowel disease, potentially restoring gut health and reducing inflammation.
How similar studies have performed: This project is developing a novel synthetic biology-based cellular medicine, building on the research team's prior findings that a specific protein (SlpA) has anti-inflammatory properties.
Where this research is happening
Rockville, UNITED STATES
- Rise Therapeutics, LLC — Rockville, United States (Active)
Researchers
- Principal investigator: Fanger, Gary — Rise Therapeutics, LLC
- Study coordinator: Fanger, Gary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.